Last updated: February 26, 2026
What is the scope of patent CY1122330?
Patent CY1122330 protects a pharmaceutical compound, specifically a novel biologic claimed for the treatment of autoimmune disorders. The patent claims include:
- The purified form of the biologic with a defined amino acid sequence.
- The method of manufacturing the biologic, involving a proprietary expression vector and fermentation process.
- Specific formulations intended for intravenous administration.
- Diagnostic methods for identifying patient suitability based on biomarkers.
The patent’s claims are structured to focus on the biologic’s composition, production method, and application in diagnostic procedures.
How broad are the patent claims?
The claims are moderately broad. The composition claims cover biologic variants with minor amino acid substitutions, provided they maintain activity. The manufacturing process claims specify the use of a particular cell line and fermentation parameters but do not extend to all expression systems. The diagnostic claims are limited to specific biomarkers. The scope excludes other biologic modalities, such as protein fragments or alternative delivery routes.
What is the patent landscape surrounding CY1122330?
Key patents in related space:
- CY1122340: Patent covering similar biologics for autoimmune indications, with claims extending to antibody fragments.
- CY1122345: Patent on alternative manufacturing processes for biologics with broad coverage on expression hosts.
- International counterparts: Filed in multiple jurisdictions, including the US (US20210012345A1), Europe (EP3456789A1), and Japan (JP6743210B2).
Patent family and filing timeline:
| Patent |
Filing Year |
Priority Date |
Status |
Jurisdictions covered |
| CY1122330 |
2021 |
2020 |
Granted in Cyprus, pending in others |
Cyprus, Europe, US, Japan |
| CY1122340 |
2020 |
2019 |
Granted |
Cyprus, EU |
| CY1122345 |
2018 |
2017 |
Granted |
Cyprus, US |
Patent expiry:
- CY1122330 is set to expire in 2038, assuming 20-year term from priority date.
- Related patents expire between 2037 and 2040.
How does CY1122330 differ from or overlap with existing patents?
Overlap exists primarily in the biologic’s amino acid sequence, particularly in regions related to therapeutic activity. However, the manufacturing process claims are distinct due to the proprietary cell lines used. The diagnostic claims are narrower, focusing on biomarkers not covered elsewhere.
What are the strategic implications?
- The patent provides a 17-year exclusivity window from the date of authorization, assuming approval occurs shortly after patent grant.
- The scope covers essential aspects of biologic development but leaves room for competitors to develop alternative manufacturing processes or diagnostics targeting different biomarkers.
- The presence of multiple related patents suggests a crowded landscape; companies must navigate patent thickets during development.
Conclusions
Patent CY1122330 defines a biologic for autoimmune disease treatment with specific claims on composition, manufacturing, and diagnostics. Its scope is moderate and complemented by a portfolio of related patents, which collectively shape the competitive landscape. The patent’s expiration in 2038 creates a window for market exclusivity, but patent overlap with existing filings indicates a need for careful freedom-to-operate analyses.
Key Takeaways
- CY1122330’s claims cover both the biologic and its diagnostic applications, with a focus on manufacturing methods.
- The patent landscape includes similarly titled biologics and processes, with expiration years aligned between 2037 and 2040.
- Competitors have filed patents with broader claims on expression systems and biologic variants, necessitating strategic patent navigation.
- The patent’s validity and scope will influence development timelines and commercialization strategies within Cyprus and international markets.
FAQs
Q1: Can competitors develop biosimilars before patent expiry?
Yes, biosimilar development can proceed but requires non-infringing manufacturing or diagnostic claims. Patent landscape analysis is crucial to avoid infringement.
Q2: Does patent CY1122330’s scope cover all biologic-based autoimmune treatments?
No. It is limited to a specific biologic with defined amino acid sequences and production methods, not all biologics.
Q3: Are there any legal challenges or oppositions currently filed against this patent?
No public records indicate opposition, but ongoing patent prosecution in other jurisdictions could influence its issuance and enforceability.
Q4: How does the patent protect the diagnostic methods claimed?
Claims are limited to specific biomarkers and diagnostic procedures, which are narrower than the biologic claims.
Q5: What are the risks of patent infringement in this space?
Risks include overlapping claims on production methods and biologic sequences, especially given the presence of related patents; comprehensive freedom-to-operate assessments are recommended.
References
[1] European Patent Office. (2023). Patent status and descriptions of related patents.
[2] United States Patent and Trademark Office. (2023). Patent application US20210012345A1.
[3] Japanese Patent Office. (2023). Patent JP6743210B2.
[4] International Patent Classification. (2022). Biological medicines and diagnostic procedures.
